期刊文献+

多巴丝肼对帕金森病患者血浆同型半胱氨酸和脑血流动力学的影响 被引量:11

下载PDF
导出
摘要 目的观察多巴丝肼(美多芭)对帕金森病患者(PD)血浆同型半胱氨酸(Hcy)和脑血流动力学的影响,探讨美多芭对PD患者脑血流的影响。方法 PD患者32例,均经美多芭治疗5个月,采用ELISA法测定治疗前后患者血浆Hcy,应用经颅多普勒(TCD)各项参数(Vm,PI)评价治疗前后脑血流变化,统计分析比较治疗前后Hcy和MV,PI的变化,并分析Hcy变化和脑血流变化的相关性。结果美多芭治疗5个月后患者血浆Hcy显著升高(P<0.01),而MV和PI无显著变化,相关性分析表明Hcy变化同Vm变化成负相关,同PI变化成正相关,与服用美多芭剂量无明显相关。结论美多芭治疗5个月可致PD患者血浆Hcy升高,但对其脑血流动力学尚无明显影响。
作者 王永久 程焱
出处 《中国老年学杂志》 CAS CSCD 北大核心 2012年第3期486-487,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献5

  • 1于会艳,秦斌,曾湘豫,孙云闯.帕金森病患者伴发高同型半胱氨酸血症的相关因素分析[J].卒中与神经疾病,2010,17(2):83-85. 被引量:8
  • 2Lentz SR.Mechanisms of homocysteine-induced atherothrombosis[J].JThromb Haemost,2005;3(8):1646-54.
  • 3Rogers JD,Sanchez-Saffon A,Frol AB,et al.Elevated plasma homocys-teine levels in patients treated with levodopa:association with vasculardisease[J].Arch Neurology,2003;60:59-64.
  • 4Nakaso K,Yasui K,Kowa H,et al.Hypertrophy of IMC of carotid arteryin Parkinson's disease is associated with.L-DOPA,homocysteine,andMTHFR genotype[J].J Neurol Sci,2003;15;207(1-2):19-23.
  • 5Vokatch N,Grotzsch H,Mermillod B,et al.Is cerebral autoregulation im-paired in Parkinson's disease?A transcranial Doppler study[J].J NeurolSci,2007;254(1-2):49-53.

二级参考文献10

  • 1Allain P,Le Bouil A,Cordillet E,et al.Sulfate and cysteine levels in the plasma of patients with Parkinson′s disease.Neurotoxicology,1995,16(3):527-529.
  • 2Seshadri S,Beiser A,Selhub J,et al.Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.N Engl J Med,2002,346:476-483.
  • 3Haynes WG.Hyperhomocysteinemia,vascular function and atherosclerosis:effects of vitamins.Cardiovasc Drugs Ther,2002,16:391-399.
  • 4Miller JW,Selhub J,Nadeau MR,et al.Effect of L-dopa on plasma homocysteine in PD patients:relationship to B-vitamin status.Neurology,2003,60 (7):1125-1129.
  • 5Yasui K,Nakaso K,Kowa H,et al.Levodopa-induced hyperhomocysteinaemia in Parkinson′s disease.Acta Neurol Scand,2003,108(1):66-67.
  • 6Blandini F,Fancellu R,Martignoni E,et al.Plasma homocysteine and L-DOPA metabolism in patients with parkinson disease.Clin Chem,2001,47(6):1102-1104.
  • 7Kuhn W,Humel T,Woitalla D,et al.Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.Neurology,2001,56(2):281-282.
  • 8Lee ES,Chen H,Soliman KF,et al.Effects of homocysteine on dopaminergic system and behavior in rodents.Neurotoxicology,2005,26(3):361-371.
  • 9Mattson MP.Will caloric restriction and folate protect against AD and PD? Neurology,2003,60(4):690-695.
  • 10Muller T,Kuhn W.Tolcapone decreases plasma level of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.Eur J Clin Phamacol,2006,62(6):447-450.

共引文献7

同被引文献97

  • 1简文佳,时晶,倪敬年,魏明清,田金洲.日常生活能力量表鉴别痴呆与轻度认知损害[J].中国老年学杂志,2014,34(4):865-868. 被引量:71
  • 2杨颖琳,史美甫.帕金森病的药物治疗[J].中国药业,2005,14(12):19-22. 被引量:19
  • 3Szyrwiel L,Pap JS,Malinka W, et al. Interactions of anti-Parkinson drug benserazide with Zn( H ), Cu( II ),Fe( II ) i-ons[J]. J Pharm Biomed Anal, 2013,76(16) :36-43.
  • 4Li HJ, Zhang MF, Chen L,et al. Nonmotor symptoms are in-dependently associated with impaired health-related quality oflife in Chinese patients with parkinson’s disease[J]. MovementDisorders,2010,25(16) :2740-2746.
  • 5Yamamoto M, Uesugi T, Nakayama T, Dopamme agonistsand cardiac valvulopathy in Parkirmon disease: a ease, controlstudy[J]. Neurology,2008,67(17) :1225~1227.
  • 6Izumi Y,Sawada H, Yamamoto N. The effect of a clinicallypractical exercise on levodopa bioavailability and motor re-sponse in patients with Parkinson disease[J]. Eur J Pharmae-ol,2007,557(2,3);132-140.
  • 7Izumi Y,Sawada H,Yamamoto N. Novel neuropmtectivemechanism of pramipexole. anti-Parkinson drug, against en-dogenous dopamine-mediated excitotoxicity[J], Clin Neurop-harmacol, 2010, 33(5) :254-266.
  • 8Skljarevski V,Zhang S,Desaiah D,et al. Duloxetine versusplacebo in patients with chronic low back pain: a 12-week,fixed-dose, randomi2ed, double-blind trial[J]. J Pain, 2010,11(12):1282-1290.
  • 9Schueler YB, Koesters M, Wieseler B, etal. A systematic re-view of duloxetine and venlafaxine in major depression? inclu-ding unpublished dala[J]. Acta PsychiatT Scand,2011, 123(4) : 247-265.
  • 10Brecht S,Desiah D,Marechal ES,etal. Efficacy and safely ofduloxetine 60 mg and 120 mg daily in patients hospitalized forsevere depression: a double-blind randomized trial [J]. J ClinPsychiatry, 2011, 72(8): 1086-1094.

引证文献11

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部